BHVN
Biohaven Ltd.
$9.45
-0.03
(-0.32%)
Mkt Cap
1.00B
Volume
1,439,359
52W Range
7.48-18.566
Sector
Healthcare
Beta
3.31
EPS (TTM)
-5.67
P/E Ratio
-1.64
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (738.82M) | (846.42M) | (408.17M) | (570.28M) | (213.80M) | (118.67M) | (528.80M) |
| EPS | -6.86 | -9.28 | -5.73 | -12.75 | -5.97 | -3.31 | -10.91 |
| Free Cash Flow | (610.15M) | (586.50M) | (334.77M) | (338.76M) | (146.78M) | (78.65M) | (379.87M) |
| FCF / Share | -5.67 | -6.43 | -4.70 | -7.57 | -4.10 | -2.20 | -7.83 |
| Operating CF | (609.44M) | (582.45M) | (331.73M) | (297.69M) | (145.84M) | (75.96M) | (377.33M) |
| Total Assets | 451.45M | 615.11M | 513.21M | 661.78M | 142.06M | 111.50M | 344.26M |
| Total Debt | 278.86M | 36.58M | 30.88M | 33.60M | 3.24M | 3.60M | 0 |
| Cash & Equiv | 229.96M | 99.13M | 248.40M | 204.88M | 76.06M | 82.51M | 316.73M |
| Book Value | 52.07M | 423.44M | 427.98M | 538.77M | 34.69M | 16.78M | (7.42M) |
| Return on Equity | -14.19 | -2.00 | -0.95 | -1.06 | -6.16 | -7.07 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (130.53M) | (145.56M) | (173.44M) | (198.15M) | (221.68M) | (186.84M) | (160.30M) | (319.77M) | (179.50M) | (144.76M) | (102.57M) | (90.35M) |
| EPS | -0.88 | -1.21 | -1.64 | -1.94 | -2.17 | -1.85 | -1.70 | -3.64 | -2.20 | -1.81 | -1.50 | -1.32 |
| Free Cash Flow | (149.92M) | (130.67M) | (145.73M) | (168.17M) | (165.59M) | (170.79M) | (141.89M) | (170.75M) | (103.08M) | (115.35M) | (96.06M) | (44.99M) |
| FCF / Share | -1.02 | -1.09 | -1.38 | -1.64 | -1.62 | -1.69 | -1.50 | -1.95 | -1.26 | -1.44 | -1.41 | -0.66 |
| Operating CF | (149.92M) | (130.66M) | (145.72M) | (167.94M) | (165.12M) | (170.74M) | (141.28M) | (167.80M) | (102.64M) | (114.88M) | (94.81M) | (44.39M) |
| Total Assets | 466.41M | 451.45M | 409.12M | 550.41M | 458.95M | 615.11M | 510.52M | 582.64M | 418.53M | 513.21M | 382.74M | 506.74M |
| Total Debt | 280.27M | 278.86M | 314.18M | 291.56M | 35.51M | 36.58M | 28.99M | 29.74M | 30.53M | 30.88M | 31.57M | 29.11M |
| Cash & Equiv | 273.07M | 229.96M | 184.85M | 165.80M | 98.42M | 99.13M | 84.39M | 239.15M | 182.71M | 248.40M | 111.70M | 147.61M |
| Book Value | 129.50M | 52.07M | (17.16M) | 134.59M | 259.50M | 423.44M | 316.01M | 383.74M | 301.45M | 427.98M | 290.01M | 387.25M |
| Return on Equity | -1.01 | -2.80 | N/A | -1.47 | -0.85 | -0.44 | -0.51 | -0.83 | -0.60 | -0.34 | -0.35 | -0.23 |
BHVN News
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026
Why Biohaven Stock Crushed it on Monday
Aberdeen Group plc Buys Shares of 693,452 Biohaven Ltd. $BHVN
SG Americas Securities LLC Grows Holdings in Biohaven Ltd. $BHVN
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of “Moderate Buy” by Brokerages
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment